Peripheral Arterial Disease Clinical Trial
Official title:
Safety and Effectiveness Evaluation of Eximo's B-Laser™ Atherectomy Device, in Subjects Affected With PAD
Verified date | February 2019 |
Source | Eximo Medical Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to assess the safety and efficacy of the use of the Eximo's B-Laser™ catheter in subjects affected with Peripheral Artery Disease (PAD) in lower extremity arteries.
Status | Completed |
Enrollment | 57 |
Est. completion date | November 20, 2020 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is = 18 years old. 2. Subject is a candidate for endovascular intervention for peripheral artery disease in the lower extremities. 3. Documented symptomatic atherosclerotic peripheral artery disease Rutherford Classification 2-4. 4. Subject has infrainguinal target lesion(s) with any type of stenosis (naïve or recurrent) estimated to be =70% based on CT angiogram or other imaging modality. 5. At least one patent tibial run-off vessel at baseline. 6. Subject is capable and willing to comply with the scheduled follow up. 7. Subject is able and willing to sign a written informed consent form (ICF). Intraoperative inclusion criteria (by fluoroscopy angiogram): 1. Reference vessel lumen diameter proximal to target lesion is =150% of the outer diameter of the B-Laser™ to be used. 2. Target lesion has been crossed with a guidewire within the true lumen. 3. Target lesion has a stenosis estimated to be =70%. Exclusion Criteria: 1. Target lesion is in a vessel graft or synthetic graft. 2. Target lesion length >25 cm. 3. Endovascular or surgical procedure performed less than or equal to 30 days prior to the index procedure OR Planned endovascular or surgical procedure 30 days after the index procedure. 4. Intent to use other atherectomy device in the same procedure. 5. Flow limiting dissection proximal to, distal to or in the target lesion. 6. Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months. 7. Evidence or history of aneurysm in the target vessel within the past 2 months. 8. History of bleeding diathesis, coagulopathy or inability to accept blood transfusions. 9. History of heparin-induced thrombocytopenia (HIT). 10. Significant acute or chronic kidney disease with a creatinine level >2.5 mg/dl, and/or requiring dialysis. 11. Any thrombolytic therapy within 2 weeks of the index procedure. 12. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days. 13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated. 14. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated. 15. Serious illness that may affect subject compliance to protocol and at a minimum the 30-day follow-up. 16. Participating in other clinical study that involves any kind of intervention, including pharmaceutical. 17. Issue that in the judgment of the investigator, may affect the results of the study. 18. Subject is pregnant or planning to become pregnant during the study period. Intraoperative exclusion criteria (by fluoroscopy angiogram): 1. Total occlusion of the Target lesion that cannot be crossed in the true lumen by 0.014" GW. 2. Target lesion length >25 cm. 3. Reference vessel lumen diameter proximal to target lesion is <150% of the outer diameter of the B-Laser™. 4. Any clinical and/or angiographic complication attributed to the use of another device prior to the study procedure. 5. Flow limiting dissection proximal, distal or in the target lesion. |
Country | Name | City | State |
---|---|---|---|
Poland | Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach | Katowice | |
Poland | Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu | Poznan |
Lead Sponsor | Collaborator |
---|---|
Eximo Medical Ltd. | KCRI |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With 30 Day Freedom From Major Adverse Events | Need for emergency surgical revascularization of the target limb Unplanned target limb amputation above the ankle Clinically driven Target Lesion Revascularization (TLR) Cardiovascular related deaths |
30 days post procedure | |
Primary | Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (1) | (*NOTE: Device- or procedure-related AE refers only to the ATHERECTOMY PROCEDURE (with B-Laser™) and not the entire index procedure.) Clinically Significant Perforations requiring intervention Clinically Significant Dissections requiring intervention Clinically Significant Embolus requiring intervention Clinically Pseudo-aneurysm requiring intervention |
Perioperative (until discharge), an average of 6 days | |
Primary | Number of Lesions With Technical Success Rate: the Ability of the B-Laser™ Catheter to Cross the Target Lesion Stenosis Over the Wire. | The technical success will be evaluated visually by the performing physician during procedure by fluoroscopy. It is evaluated per lesion and not per subject | Intraoperative (during the index procedure, after B-Laser™ catheter crossing, before adjunctive therapy) | |
Secondary | Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2) | (*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.) Emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator Flow limiting dissection |
Perioperative (until discharge), an average of 6 days | |
Secondary | Number of Participants With 30 Day Freedom From Device/Procedure* Related Adverse Events | (*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.) Clinically Significant Dissections requiring intervention Clinically Significant Embolus requiring intervention Clinically Pseudo-aneurysm requiring intervention |
30 days post procedure | |
Secondary | Number of Lesions With Post-intervention Residual Diameter Stenosis of <30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable | The ability of the B-Laser™ catheter to achieve a post-intervention residual diameter stenosis of <30% with adjunctive therapy assessed by fluoroscopic angiography in cases where adjunctive therapy is medically applicable | Intraoperative (at the end of the index procedure, after the last adjunctive therapy, e.g. last balloon or last stent) | |
Secondary | Change in Ankle-Brachial Index (ABI) Post B-Laser™ Device Procedure Compared to Baseline | Change in Ankle-Brachial Index (ABI) post B-Laser™ device procedure compared to baseline. ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3. The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher ABI score at the later time point represents an improvement through time and vice versa. |
baseline and 30 days, 6 months and 12 months post procedure | |
Secondary | Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline | Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline. Rutherford Classification has seven stages, from Stage 0 to Stage 6, when the lower value indicate a better outcome: 0= Asymptomatic; 1= Mild claudication; 2= Moderate claudication; 3= Severe claudication; 4= Rest pain; 5= Ischemic ulceration not exceeding ulcer of the digits of the foot; 6= Severe ischemic ulcers or frank gangrene. The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent decrease while negative results represent increases, so lower Rutherford score at the later time point represents an improvement through time and vice versa. |
baseline and 30 days, 6 months and 12 months post procedure | |
Secondary | Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline | Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline. WIQ score ranges from 0-100 with higher score indicating a better walking outcomes. The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher WIQ score at the later time point represents an improvement through time and vice versa. |
baseline and 30 days, 6 months and 12 months post procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |